Serena Di Cosimo is an expert in Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Italy). As of October 2026, ScienceLeadR ranks Serena Di Cosimo in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Serena Di Cosimo has authored 272 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 983 (community average: 125). How the SLR is computed.

LeadR Profile

983 ScienceLeadR Reputation 983
Network Map

Oncology

Subspecialties: Dermatology - Hematology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026

Source: PubMed

Fondazione IRCCS Istituto Nazionale dei Tumori

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 272

Citations

Citations: 9 659 1st author: 60 Last author: 38 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients.
PMID 42804144 — radiotherapy, breast neoplasms, male, breast neoplasms, neoplasms, multiple chronic conditions, radiology, drug-related side effects and adverse reactions, breast, therapeutics
Radiol Med20260
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)].
PMID 42541182 — radiotherapy, epidermal growth factor, mastectomy, growth, lapatinib, breast neoplasms, neoplasms, receptors, growth factor, breast, therapeutics, trastuzumab
EClinicalMedicine20260
Bioinformatics of Shallow Whole Genome Sequencing Data of Circulating Tumor Cells to Inform Cancer Diagnosis and Treatment.
PMID 42426466 — cells, whole genome sequencing, neoplastic cells, circulating, workflow, neoplasms, genome, diagnosis, therapeutics
Methods Mol Biol20260
Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.
PMID 42421646 — research design, blood, circulating tumor dna, breast neoplasms, neoplasms, breast, neoplasm, residual, therapeutics, dna
Cancer20260
Reply to Letter to the Editor on: A. G. Nerlich, J. C. Dewaal, A. Perciaccante, S. Di Cosimo, L. Cortesi, J. Wimmer, S. T. Donnell, R, Bianucci: Did Michelangelo paint a young adult woman with breast cancer in "The Flood" (Sistine Chapel, Rome)? Breast 2024, 78, 103823 by Dr. Paul Gelinsky.
PMID 42236334 — breast neoplasms, neoplasms, paint, breast
Breast20260

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 4
N/A 2
Phase 3 2
Phase 1 1

By status:

Completed 7
Active not recruiting 1
Recruiting 1

By type:

Interventional 7
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 7

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Composite Assay for HER2 positive Early stage Breast Cancer Management
NCT06762977 — genes, breast neoplasms, neoplasms, breast, prognosis, gene expression
N/ARecruiting2024

LeadR Networks

Main global connection map